9989 — Shenzhen Hepalink Pharmaceutical Co Share News
0.000.00%
Last trade - 00:00- HK$5.93bn
- HK$5.70bn
- CNY5.48bn
Brief: OrbiMed Capital's Long Position In H-Shares Of Hepalink Pharmaceutical Falls To 4.83% - Filing
Brief: Shenzhen Hepalink Pharmaceutical Plans To Issue Bonds Worth Up To 1.0 Bln Yuan
HY Revenue Rmb3.76 Billion Versus Rmb3.11 Billion
Brief: Shenzhen Hepalink Pharma Says 6-Month Net Profit Up 51.2% Y/Y
Brief: Shenzhen Hepalink Pharma Sees 6-Month Net Profit Up 40.0-60.3% Y/Y
Brief: Shenzhen Hepalink Pharmaceutical Posts QTRLY Net Profit Attributable Of RMB234.9 Million
Brief: Shenzhen Hepalink Pharmaceutical's 2021 Net Profit Down 76.5% Y/Y
Brief: Shenzhen Hepalink Pharmaceutical Says Proposed Distribution Of Final Cash Dividend Of RMB0.35/Ten Shares For Year
Brief: Shenzhen Hepalink Pharmaceutical Posts FY Revenue RMB6.42 Billion
Brief: Shenzhen Hepalink Pharmaceutical Says Expected Delay In Publication Of Audited Annual Results Announcement For Year
Brief: Shenzhen Hepalink Pharma Gets Regulatory Approval For Bond Issue
Brief: Shenzhen Hepalink Pharmaceutical Sees FY Net Profit Attributable
Brief: Shenzhen Hepalink Pharmaceutical Group Says Unit Commences Operations and Launches Its Heparin Sodium Injection In United States
Brief: Shenzhen Hepalink Pharmaceutical To Issue Corporate Bonds Worth Not Exceeding RMB1.50 Bln
Brief: Shenzhen Hepalink Pharmaceutical Plans To Issue 1.5 Bln Yuan Bonds
Brief: Shenzhen Hepalink Pharmaceutical Says Qtrly Net Profit Attributable RMB123.3 Mln
Brief: Shenzhen Hepalink Pharmaceutical Group Proposes To Expand Business Scope
Brief: Shenzhen Hepalink Pharmaceutical Group Posts HY Profit Attributable Of RMB338.2 Mln
Brief: Shenzhen Hepalink Pharmaceutical Says Inhixa Approved For Sales In Bosnia & Herzegovina